Stockscreener 앱 받기
7.30
2.96%
0.21
시간 외 거래:
7.29
-0.010
-0.14%
Kezar Life Sciences Inc 주식(KZR)의 최신 뉴스
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa
Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat
Kezar Life Sciences announces 1-for-10 reverse stock split - MSN
Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com
Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan
What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN
Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK
Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena
Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga
Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha
Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha
Kezar to discontinue mid-stage trial for lupus treatment - Reuters
Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com
Kezar to focus on AIH drug after halting lupus trial - Investing.com
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - StockTitan
Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com
Short Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Increases By 13.6% - MarketBeat
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short Interest - Defense World
Kezar Life Sciences (NASDAQ:KZR) Given "Neutral" Rating at HC Wainwright - MarketBeat
H.C. Wainwright maintains Neutral rating on Kezar shares amid acquisition bid - Investing.com UK
Concentra Biosciences proposes to buy Kezar Life Sciences - Investing.com India
Concentra Biosciences proposes to buy Kezar Life Sciences By Investing.com - Investing.com Australia
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - BioSpace
Concentra boss eyes up struggling Kezar - The Pharma Letter
Analyzing Kezar Life Sciences Inc (KZR) After Recent Trading Activity - Knox Daily
Mackenzie Financial Corp Invests $35,000 in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $80.3 million. - Marketscreener.com
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc - Yahoo Finance
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sci - GuruFocus.com
After-hours movers: Astera Labs, Saratoga Investment, Kezar Life Sciences, and more By Investing.com - Investing.com Canada
A new trading data show Kezar Life Sciences Inc (KZR) is showing positive returns. - SETE News
Post-Trade Analysis: Kezar Life Sciences Inc (KZR) Slides -2.95, Closing at 0.77 - The Dwinnex
What is the investor’s view on Kezar Life Sciences Inc (KZR)? - US Post News
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths - AOL
Polymyositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas - The Globe and Mail
US FDA puts hold on lupus trial after patient deaths - The Pharma Letter
FDA places hold on Kezar Life Sciences’ trial for lupus nephritis treatment - Clinical Trials Arena
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis - BioSpace
FDA places clinical hold on Kezar lupus drug after deaths - Investing.com India
US FDA puts Kezar Life Sciences' lupus treatment trial on hold after patient deaths - Reuters.com
Kezar zetomipzomib IND for lupus placed on FDA clinical hold (NASDAQ:KZR) - Seeking Alpha
FDA places clinical hold on Kezar lupus drug after deaths By Investing.com - Investing.com South Africa
US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial - Marketscreener.com
2.02%
0.47%
자본화:
|
볼륨(24시간):